Evidence map›Paper›PMID 25158005›Full record

ArticleTranslational psychiatry2014

Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia.

N J M van Beveren, E Schwarz, R Noll, P C Guest, C Meijer, L de Haan, S Bahn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.The international journal of neuropsychopharmacology · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

N J M van Beveren1] Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands [2] Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands [3] Department 'Nieuwe Kennis', Delta Center for Mental Health Care, Rotterdam, The Netherlands.
E SchwarzDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
R NollDepartment of Psychology, DeSales University, Center Valley, PA, USA.
P C GuestDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
C MeijerDepartment of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands.
L de HaanDepartment of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands.
S Bahn1] Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands [2] Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
University of Cambridge · GBAcademic Medical Center · NLErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular abnormalities in metabolic, hormonal and immune pathways are present in peripheral body fluids of a significant subgroup of schizophrenia patients. The authors have tested whether such disturbances also occur in psychiatrically ill and unaffected siblings of schizophrenia patients with the aim of identifying potential contributing factors to disease vulnerability. The subjects were recruited as part of the Genetic Risk and OUtcome of Psychosis (GROUP) study. The authors used multiplexed immunoassays to measure the levels of 184 molecules in serum from 112 schizophrenia patients, 133 siblings and 87 unrelated controls. Consistent with the findings of previous studies, serum from schizophrenia patients contained higher levels of insulin, C-peptide and proinsulin, decreased levels of growth hormone and altered concentrations of molecules involved in inflammation. In addition, significant differences were found in the levels of some of these proteins in siblings diagnosed with mood disorders (n=16) and in unaffected siblings (n=117). Most significantly, the insulin/growth hormone ratio was higher across all groups compared with the controls. Taken together, these findings suggest the presence of a molecular endophenotype involving disruption of insulin and growth factor signaling pathways as an increased risk factor for schizophrenia.

Indexed as

AdolescentAdultC-PeptideEndophenotypesFemaleGenetic Predisposition to DiseaseHuman Growth HormoneHumansInflammation MediatorsInsulinIntracellular Signaling Peptides and ProteinsMaleProinsulinReference ValuesRisk FactorsSchizophreniaC-PeptideHuman Growth HormoneInflammation MediatorsInsulinIntracellular Signaling Peptides and ProteinsProinsulin

Identifiers

PMID25158005
PMCPMC4150237
OpenAlexW2000931591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.